SOLICITATION NOTICE
68 -- SNP Panel, Activation Kit, Assay Kits and Array Matrix
- Notice Date
- 8/7/2009
- Notice Type
- Presolicitation
- NAICS
- 325413
— In-Vitro Diagnostic Substance Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-90173-AV
- Archive Date
- 9/1/2009
- Point of Contact
- Ashley L. Virts,
- E-Mail Address
-
virtsa@mail.nih.gov
(virtsa@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The National Cancer Institute (NCI), Division of Cancer Epidemiology (DCEG), Hormonal and Reproductive Epidemiology Branch (HREB) plans to procure on a sole source basis, an SNP Panel, Activation Kit, Assay Kits and Array Matrix from Illumina, Inc, 9885 Towne Center Drive. San Diego, California 92121. The supplies herein are being procured in accordance with the simplified acquisition procedures authorized by FAR Part 13.106-(b) (1). The North American Industry Classification System Code is 325413 and the business size standard is 500 employees. The goal of the HREB is to identify DNA methylation markers to be integrated with standardized histological typing and grading to improve the classification of endometrial and ovarian tumors for epidemiologic studies. The new classification to identify a marker panel for early detection will contribute to re-assess risk factor associations. DNA methylation of gene promoters has been linked to silencing of specific tumor suppressor genes and recognized in cancer precursors of many organs, suggesting that it represents an early causal step in carcinogenesis. Although mRNA profiling has led to new molecular classifications in many tumor sites, the liability of RNA species limits their value as early detection markers in clinical practice. In contrast, DNA methylation markers are stable, somatically heritable, and can be measured in fixed tissues. In addition, methylation markers have been detected in cell-free DNA from body fluids, such as serum and in DNA extracted from cells collected from many different types of specimens. The lab proposes to characterize methylation patterns for endometrial and ovarian cancer using formalin-fixed, paraffin-embedded (FFPI) tissues. The effort will yield a methylation marker panel with which to assess etiologic heterogeneity and early detection markers in various specimen types. Epigenetic modifications, such as DNA methylation are involved in many carcinogenic processes. Several methods have been developed to study DNA methylation, but few allow analyzing several methylation targets in parallel. In addition, most assays are restricted to studying fresh frozen tissue, but do not work in formalin-fixed paraffin embedded (FFPE) tissue. However, most epidemiologic studies do not collect fresh frozen tissue and are limited to conventional FFPE material as the only source of tunor DNA. The Illumina Golden Gate assay is a high throughput assay that analyzes more than 1500 methylated sites from 800 cancer related genes simultaneously using low amounts of tumor DNA. The additional various Illumina assays are the only validated high-throughput methylation assay validated and shown to reliably measure DNA methylation in FFPE tissue. The HREB, in collaboration with another NCI lab, plan to analyze DNA methylation patterns in two population based studies which both have only paraffin material available, so these assays are critical to the continuation of the study. The lab has validated and developed the protocols to use the assays on DNA derived from FFPE. The lab is not aware of any other source providing high throughput, wide-coverage methylation assay validated for FFPE specimens. For these reasons, Illumina is a sole source provider for supplies regarding the studies outlined in this procurement. Delivery Date: 1 to 2 weeks after award. This is not a request for competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow the researcher to determine if the party can meet this requirement. One (1) original and one (1) copy of the capability statement must be received in the contracting office by 1:00 p.m. ET on August 17, 2009. All questions must be in writing and can be faxed to 301-402-4513 or sent via email to Ashley Virts: virtsa@mail.nih.gov. It is the vendor’s responsibility to ensure questions have been received. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, contractor must have valid, updated registration and certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Application (ORCA). Please reference NCI-90173-AV on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-90173-AV/listing.html)
- Record
- SN01903791-W 20090809/090808000749-86ec00790ca62bba3bbb9e62f64e82c7 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |